Pactimibe sulfate

Small molecule

Daiichi Sankyo

Pactimibe sulfate is one of 7 small molecule programs targeting Carotid Artery Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carotid Artery DiseaseActive, not recruiting

Carotid Artery DiseasePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Carotid Artery Disease

#DrugCompanyPhaseTrials

Lithobid

SSolvay Pharmaceuticals

Optison

1 3

Plavix

Bayer Aspirin

Zocor

DPA-714

UUniversity of Alabama at Birmingham

Phase 1

1 7

Pactimibe sulfate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carotid Artery Disease1 trial

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2/3·NCT00151788·796 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pactimibe sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pactimibe sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pactimibe sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Daiichi Sankyo

Pactimibe sulfate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carotid Artery Disease1 trial

References

Drug Info

Quick Facts

Related News